Larvol Delta - Arthrosi-Therapeutics-Completes-Enrollment-in-Pivotal-Phase-3-REDUCE-2-Trial-of-AR882-for-the-Treatment-of-Gout-and-Tophaceous-Gout

AR882 - Arthrosi

https://www.prnewswire.com/news-releases/arthrosi-therapeutics-completes-enrollment-in-pivotal-phase-3-reduce-2-trial-of-ar882-for-the-treatment-of-gout-and-tophaceous-gout-302390495.html

Mar 5, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next